J. B. Chemicals & Pharmaceuticals Limited

NSEI:JBCHEPHARM Stock Report

Market Cap: ₹290.3b

J. B. Chemicals & Pharmaceuticals Valuation

Is JBCHEPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JBCHEPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JBCHEPHARM (₹1867.6) is trading above our estimate of fair value (₹560.35)

Significantly Below Fair Value: JBCHEPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JBCHEPHARM?

Key metric: As JBCHEPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JBCHEPHARM. This is calculated by dividing JBCHEPHARM's market cap by their current earnings.
What is JBCHEPHARM's PE Ratio?
PE Ratio47.5x
Earnings₹6.11b
Market Cap₹290.29b

Price to Earnings Ratio vs Peers

How does JBCHEPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for JBCHEPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.6x
GLAND Gland Pharma
45.3x25.8%₹313.2b
AJANTPHARM Ajanta Pharma
41x16.3%₹358.9b
EMCURE Emcure Pharmaceuticals
48.9x25.3%₹277.5b
524742 Caplin Point Laboratories
39.1x13.6%₹192.8b
JBCHEPHARM J. B. Chemicals & Pharmaceuticals
47.5x19.4%₹290.3b

Price-To-Earnings vs Peers: JBCHEPHARM is expensive based on its Price-To-Earnings Ratio (47.5x) compared to the peer average (43.6x).

Price to Earnings Ratio vs Industry

How does JBCHEPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.8xn/aUS$77.16m
524652 Ind-Swift
3xn/aUS$19.01m
No more companies available in this PE range
JBCHEPHARM 47.5xIndustry Avg. 36.3xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JBCHEPHARM is expensive based on its Price-To-Earnings Ratio (47.5x) compared to the Indian Pharmaceuticals industry average (36.3x).

Price to Earnings Ratio vs Fair Ratio

What is JBCHEPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JBCHEPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47.5x
Fair PE Ratio41.9x

Price-To-Earnings vs Fair Ratio: JBCHEPHARM is expensive based on its Price-To-Earnings Ratio (47.5x) compared to the estimated Fair Price-To-Earnings Ratio (41.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JBCHEPHARM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,867.60
₹2,179.15
+16.7%
8.6%₹2,355.00₹1,686.00n/a13
Dec ’25₹1,735.30
₹2,173.77
+25.3%
8.4%₹2,330.00₹1,686.00n/a13
Nov ’25₹1,960.30
₹2,118.00
+8.0%
8.5%₹2,343.00₹1,651.00n/a13
Oct ’25₹1,834.95
₹2,105.69
+14.8%
8.1%₹2,255.00₹1,651.00n/a13
Sep ’25₹1,953.80
₹2,086.17
+6.8%
8.1%₹2,230.00₹1,651.00n/a12
Aug ’25₹1,912.55
₹1,975.42
+3.3%
7.3%₹2,200.00₹1,631.00n/a12
Jul ’25₹1,792.80
₹1,975.42
+10.2%
7.3%₹2,200.00₹1,631.00n/a12
Jun ’25₹1,771.90
₹1,929.83
+8.9%
10.1%₹2,200.00₹1,519.00n/a12
May ’25₹1,905.25
₹1,881.73
-1.2%
10.1%₹2,200.00₹1,500.00n/a11
Apr ’25₹1,695.55
₹1,886.70
+11.3%
10.9%₹2,200.00₹1,500.00n/a10
Mar ’25₹1,531.40
₹1,886.70
+23.2%
10.9%₹2,200.00₹1,500.00n/a10
Feb ’25₹1,685.35
₹1,746.80
+3.6%
8.3%₹1,970.00₹1,471.00n/a10
Jan ’25₹1,615.60
₹1,689.80
+4.6%
8.0%₹1,860.00₹1,367.00₹1,878.2010
Dec ’24₹1,460.45
₹1,566.32
+7.2%
11.4%₹1,775.00₹1,137.50₹1,735.3011
Nov ’24₹1,400.15
₹1,465.27
+4.7%
10.9%₹1,657.00₹1,137.50₹1,960.3011
Oct ’24₹1,482.10
₹1,465.23
-1.1%
10.9%₹1,657.00₹1,137.50₹1,834.9511
Sep ’24₹1,398.08
₹1,422.05
+1.7%
12.3%₹1,657.00₹1,137.50₹1,953.8011
Aug ’24₹1,287.68
₹1,181.75
-8.2%
8.0%₹1,340.00₹951.50₹1,912.5512
Jul ’24₹1,183.48
₹1,179.25
-0.4%
7.9%₹1,340.00₹951.50₹1,792.8012
Jun ’24₹1,058.38
₹1,164.64
+10.0%
7.2%₹1,268.00₹951.50₹1,771.9011
May ’24₹1,064.93
₹1,138.40
+6.9%
6.0%₹1,237.50₹1,040.00₹1,905.2510
Apr ’24₹988.18
₹1,137.40
+15.1%
6.1%₹1,237.50₹1,030.00₹1,695.5510
Mar ’24₹995.93
₹1,137.40
+14.2%
6.1%₹1,237.50₹1,030.00₹1,531.4010
Feb ’24₹1,010.40
₹1,140.55
+12.9%
4.8%₹1,230.00₹1,050.00₹1,685.3510
Jan ’24₹972.25
₹1,140.55
+17.3%
4.8%₹1,230.00₹1,050.00₹1,615.6010

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:09
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

J. B. Chemicals & Pharmaceuticals Limited is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
null nullAsian Markets Securities Private Limited
Vijayaraghavan SwaminathanAvendus Spark